Clinical Trial Detail

NCT ID NCT03680521
Title Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.

clear cell renal cell carcinoma


MGCD516 + Nivolumab

Age Groups: adult senior

No variant requirements are available.